Related Experiment Video
Updated: Jan 7, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell
Tingting Cui1,2, Siyi Liu1,2, Tingting Wang3
1Department of Clinical Laboratory, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Background:
During the COVID-19 pandemic, diverse vaccine strategies were applied globally, yet most relied on immunogenicity evaluations and bridging trials rather than retrospective assessment through real-world infections. This limited understanding of protective mechanisms under natural variant exposure.
Methods:
A retrospective cohort study of real-world BA.5 infections was used to analyze the protective efficacy of Ad5-nCoV booster vaccination (A-A). Multi-layered immune profiling was performed, including neutralizing antibodies (NAbs), single-cell BCR sequencing (BCR usage), transcriptomic profiling (RNA-seq), antibody-dependent cellular cytotoxicity (ADCC), natural killer (NK) cell cytotoxicity, and virus-specific T cell immunity. These were integrated to dissect A-A-induced protection mechanisms.
Results:
The A-A conferred 48% effectiveness against symptomatic BA.5 infection (115/239) compared to the three doses of inactivated vaccine (I-I-I), which showed 10% effectiveness (4/39). Specifically, in the A-A group, 52% (124/239) of individuals experienced symptomatic infection, 38% (90/239) had asymptomatic infection, and 10% (25/239) remained uninfected. Compared to I-I-I, A-A induced significantly higher NAbs against BA.5 (GMT = 180 vs. I-I-I GMT = 54) and comparable anti-WT NAbs (GMT = 358 vs. 226), despite lower anti-S IgG levels (GMT = 6441 vs. 12,228) at 2 months post BA.5 infection. Single-cell BCR analysis revealed broader neutralizing antibody clone types in A-A, dominated by IGHV4-39 usage with elevated somatic mutation frequency. Additionally, transcriptomic and functional assays demonstrated an enhanced NK cell-mediated ADCC response and cytotoxicity against K562 target cells in A-A.
Conclusions:
Ad5-nCoV booster vaccination confers enhanced protection against symptomatic BA.5 infection through cross-reactive NAbs with expanded epitope breadth and NK cell-mediated innate immunity enhancement. This retrospective study provides insights into the immunogenicity and molecular mechanisms of two vaccination strategies against real-world BA.5 infection, highlighting Ad5-based technology's efficacy. It provides guidance for future vaccination strategies against emerging Disease X, emphasizing the value of retrospective real-world analyses in vaccine development.
More Related Videos
Related Concept Videos
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
00:42Cross-reactivity
01:51Vaccinations
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...